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Abstract 
The mapping of post-translational modifications (PTMs) of proteins can be addressed by 
bottom-up proteomics strategy using proteases to achieve the enzymatic digestion of the 
biomolecule. Glycosylation is one of the most challenging PTM to characterize due to its 
large structural heterogeneity. In this work, two Immobilized Enzyme Reactors (IMERs) 
based on trypsin and pepsin protease were used for the first time to fasten and improve the 
reliability of the specific mapping of the N-glycosylation heterogeneity of glycoproteins. The 
performance of the supports was evaluated with the digestion of human Chorionic 
Gonadotropin hormone (hCG), a glycoprotein characterized by four N- and four O-
glycosylation sites, prior to the analysis of the digests by nanoliquid chromatography 
coupled to tandem mass spectrometry (nanoLC-MS/MS). Firstly, the repeatability of the 
nanoLC-MS/MS was evaluated and a method to control the identification of the identified 
glycans was developed to validate them regarding the retention time of glycopeptides in 
reversed phase nanoLC separation. The repeatability of the digestion with trypsin-based 
IMER was evaluated on the same hCG batch and on three independent batches with 
common located glycans up to 75%. Then, the performance of the IMER digestions was 
compared to in-solution digestions to evaluate the qualitative mapping of the glycosylation. 
For the first time, the complementarity of trypsin and pepsin was illustrated for the 
glycosylation mapping. The potential of IMERs for was illustrated with the comparison of 
two hCG-based drugs, Ovitrelle® and Pregnyl®. 
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1. Introduction 
The human proteome is composed of a large and dynamic number of proteins as it has been 
estimated to more than one million proteoforms [1], while the human genome has only 
approximately 20,000 protein-coding genes [2]. This diversity is partially explained by post-
translational modifications (PTMs) that correspond to covalent modifications of chemical 
moieties on a protein after its translation. These numerous modifications (phosphorylation, 
acetylation, amidation, glycosylation …) can alter the activity of the modified proteins and 
efficient analytical methods are required to elucidate the composition of each proteoform 
[3–5]. Glycosylation is one of the most challenging PTM to characterize because of its 
heterogeneity (N- or O-glycosylation) and its high relative molecular weight (up to several 
kDa) [6]. Still, there is a need to investigate the glycosylation heterogeneity of a protein 
because it is tightly related to the protein folding, stability or immune response, and thus 
abnormal glycosylation is often found on the pathways to genetic disorders. Indeed, it was 
observed, in 2017, that more than half of genetic disorders may be due to abnormal N-
glycosylation [7]. Their structure has the advantage to be conserved and well-known: it 
consists in a common core structure Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAc with 
GlcNAc-initiated antennas or Man residues bound on the terminal Manα residues. A sole β1–
4-linked GlcNAc residue attached to the β-mannose of the N-glycan core is defined as 
bisecting. According to the type of antennae, one can distinguish so-called high mannose, 
hybrid, and complex N-glycans. 
The characterization of glycoproteins can be considered by their analysis at the intact level 
that has the advantage to preserve the integrity of the analyzed proteoforms and the 
combination of their potential glycosylation sites [8]. Due to the potential high number of 
glycoforms, they first need to be separated, using of liquid chromatography (LC) or capillary 
electrophoresis to ensure their ionization in mass spectrometry (MS). Yet, this route faces 
challenges such as the lack of resolution and their low solubility in organic solvents involved 
for their separation, and their potential bad ionization in MS [9]. Moreover, high-resolution 
high-accuracy MS is required to help the identification of such heterogeneous molecules. 
An alternative for glycosylation mapping is to use a glycosidase (e.g. PNGase F) that cleaves 
the bond between asparagine and the first GlcNAc (i.e. between the peptide and the N-
glycan), releasing the N-glycans [3]. N-glycan mapping, or glycomics, will produce a global 
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view of the N-glycosylation diversity of a single protein, biological fluid, cell type or cell 
compartment. Note that the N-glycosylation population can be obtain with the use of 
pronase E that can digest the protein in very small peptides that can be easily analysed for 
glyco-mapping [10,11]. Yet, one should notice that this approach is very expensive and if 
more than one glycosylation site is present on the protein, or if the sample contains several 
proteins, the information about the location is lost.  
The third alternative to characterize a glycoprotein is the so-called bottom-up approach and 
is the most used to date [12]. Each protein is treated to generate proteolytic peptides using 
endoproteases that are next analyzed and N-glycans can be localized on the detected N-
glycopeptides by sequencing using MS/MS fragmentation. The digestion with the protease is 
carried out during 3 to 16 hours (overnight) in solution with sufficiently high 
enzyme/substrate (E/S) ratio to decrease the duration of digestion. Yet, autoproteolysis of 
proteases increases with high E/S ratio, thus explaining the ratio of about 1:50 that can be 
found in the literature [13,14]. The development of Immobilized Enzyme Reactors (IMERs) 
overcomes this limitation by immobilizing proteases. High E/S ratio up to 4,000 have been 
reported [15], leading to a digestion time of less than one hour for greater digestion yields. 
These IMERs also have the advantage to be reusable and easily automated. Numerous IMERs 
based on the immobilization of trypsin [4,16–20], and to a lesser extent of pepsin [15,21,22], 
have been reported in the literature. Yet, the focus was set on the identification of proteins 
and few information was given on PTMs. Therefore, the performance of the support in terms 
of digestion yield, repeatability of the digestion, comparison with digestions in solution were 
evaluated on peptides without consideration of PTMs. The objective of this work was to 
prepare and use protease-based IMERs to map the glycosylation heterogeneity of a 
glycoprotein.  
We selected a highly glycosylated protein, the human chorionic gonadotropin (hCG), which is 
the hormone specific to pregnancy. Carbohydrate moieties represent ± 30% of its molecular 
weight. hCG is a heterodimer of the α subunit (hCGα) and the β subunit (hCGβ) with two N-
glycosylation sites on each subunit (respectively noted αN52, 
αN78, 
βN13, and 
βN30 in order of 
appearance in the amino acid sequence) and four O-glycosylation sites on hCGβ [23,24]. 
Four hCGβ have been reported on Uniprot database (P0DN86, P0DN87, Q6NT52, A6NKQ9). 
Several studies used an overnight digestion in solution with trypsin for the characterization 
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of N-glycosylation heterogeneity of a recombinant hCG [13,25]. Recently, Zhu et al. were 
able to map the glycosylation heterogeneity of the digested protein on each glycosylation 
site. They manually implemented thresholds for the automated validation of the 
glycopeptides identification. In this study, IMERs were used for the first time for 
glycosylation characterization and localization, hCG being used as a model glycoprotein. Two 
complementary endoproteases, trypsin and pepsin, were used to obtain more information 
on the glycosylation mapping. The performances and potential of the IMERs were evaluated 
with the digestion of two hCG-based drugs. Validation of N-glycans structures based on both 
chromatographic and mass spectrometry data was performed after nanoLC-MS/MS analysis 
of the digest. 
2. Materials and methods 
2.1. Reagents and analytes 
Trypsin from bovine pancreas (≥10,000 BAEE units mg-1 protein), pepsin from porcine gastric 
mucosa (3,200-4,500 units mg-1 protein), cyanogen bromide-activated Sepharose 4B, 
dithiothreitol (DTT), iodoacetamide (IAM), sodium chloride (99%), Trizma hydrochloride 
(TRIS) (99%), sodium acetate (99%), sodium azide (99%), glycine (99%), hydrochloric acid 
(1 M), 0.5 mL centrifugal filters (10 kDa), and bicinchoninic acid assay (BCA) protein assay 
reagents were purchased from Sigma Aldrich (Saint-Quentin Fallavier, France). Potassium 
chloride (99.5%), sodium bicarbonate (99.5%), disodium hydrogen phosphate (99%), formic 
acid (FA) (99%), and potassium dihydrogen phosphate (99.5%) were ordered from VWR 
(Fontenay-sous-Bois, France). LC/MS Grade acetonitrile (ACN) and trifluoroacetic acid (TFA) 
were purchased from Fischer Chemical (Illkirch, France). Deionized water was obtained from 
a Milli-Q purification system (Millipore, Molsheim, France). 
Two hCG-based drugs were used: Ovitrelle® (Organon, Oss, The Netherlands) and Pregnyl® 
(Serono Europe Ltd, London, UK). Ovitrelle® (recombinant protein from Chinese Hamster 
Ovary cells, r-hCG) was conditioned as a 500 µg mL-1 solution in water. Pregnyl® (hCG 
purified from urine of pregnant women, u-hCG) was obtained as a lyophilized powder (5,000 
UI). Considering that 1 UI corresponds to 0.092 µg [26], the drug was solubilized to a final 
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concentration of 500 µg mL-1 in water. The hCG samples were aliquoted and stored at -20°C 
for later use. 
2.2. Preparation of IMERs 
The procedure was adapted from previous studies from our group [15,27]. Briefly, 40 mg of 
Sepharose was swollen with 2 mL of HCl (1 mM). The Sepharose was washed twice either 
with 1.8 mL of bicarbonate buffer (NaHCO3 0.1 M, NaCl 0.5 M, pH 8.3) for trypsin 
immobilization or 1.8 mL of acetate buffer (CH3CO2Na 0.1 M, NaCl 0.5 M, pH 5.8) for pepsin 
immobilization. 1.7 mL of enzyme solution (4 mg mL-1) was incubated for 18 h at 4°C. Then, 
the enzyme-coupled Sepharose was introduced into a precolumn (2 mm i.d. x 20 mm, 2 µm, 
Upchurch, Interchim, Asnières, France). The supernatant was kept for further evaluation of 
the grafting yield. 
Trypsin-based IMER (T-IMER) was washed with 48 mL of TRIS buffer (0.1 M, pH 8.0). Acetate 
buffer (CH3CO2Na 0.1 M, NaCl 0.4 M, pH 4.0) and bicarbonate buffer were successively 
percolated through the IMER thrice to remove unbound trypsin. Finally, the IMER was stored 
at 4°C in PBS buffer (NaCl 10 mM, Na2HPO4 10 mM, KCl 1 mM, KH2PO4 1 mM, NaN3 0.1% 
(w/w), pH 7.4). 
Pepsin-based IMER (P-IMER) was washed with 48 mL of glycine buffer (0.2 M, pH 5.0). 
Acetate buffer (CH3CO2Na 0.1 M, NaCl 0.5 M, pH 5.8) and an acidic solution (HCl 0.1 mM, 
NaCl 0.5 M) were successively percolated through the precolumn thrice to remove unbound 
pepsin. Finally, the IMER was stored at 4°C in FA solution (pH 3.0, 0.2‰ v/v). 
The amount of bound proteases was evaluated with an indirect bicinchoninic acid assay [28]. 
The calibration curves (5 points) were prepared from 0.1 to 2 mg mL-1 of each protease. 
10 µL of supernatant were introduced in a well of a 96-microwell plate. Then, 100 µL of 
working reagent (bicinchoninic acid and copper (II)) were added. The reaction was 
performed during 30 min at 37°C under agitation at 300 rpm. After cooling down at room 
temperature, the absorbance was measured at 562 nm in every well with a UV-
spectrophotometer (SpectraMax M2, Molecular Devices, St Gregoire, France). The grafting 
yield was determined by the ratio between the amount of protease recovered in the 
supernatant with the amount introduced. 
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2.3. Sample preparation 
The two hCG-based drug stock solutions (r-hCG and u-hCG) were first filtered on Microcon 
10 kDa membrane filter for 45 min at 12,000 G to remove small size additives from drug 
formulation. 150 µL of TRIS buffer (TRIS 50 mM, CaCl2 10 mM, pH 8.0) was added twice to 
clean the drug. The proteins were reduced in 5 mM DTT at 56°C for 40 min and alkylated in 
25 mM IAM at room temperature for 20 min in the dark. Denatured hCG was washed three 
times on centrifugal membranes (5 min at 16,800 G) with the digestion buffer of each 
protease: TRIS buffer (TRIS 50 mM, CaCl2 10 mM, pH 8.0) for trypsin, FA pH 2.2 (0.25‰ v/v) 
for pepsin was added. The final volume was adjusted with the same buffer to get a final 
concentration of hCG of 500 µg mL-1. 
2.4. Digestion procedures 
2.4.1. Digestion on IMERs 
The protocol of digestion was adapted from previous studies from our group [15,27]. Briefly, 
2.5 µg of hCG were introduced in a 5 µL sample loop set on a six-port switching valve 
connected to an isocratic pump (LC-10 AS, Shimadzu, Champs-sur-Marne, France) and to the 
IMER set in an independent oven (Croco-cil oven, Interchim, Montluçon, France). Then, the 
protein was transferred on the IMER with the digestion buffer at 50 µL min-1. The digestion 
was carried-out during 30 min at 37°C using a « stop-flow » approach. Finally, 100 µL of the 
digestion buffer were percolated to collect both peptides and glycopeptides. 
2.4.2. Digestion in solution 
Samples were digested in solution in the same buffers as IMERs with an enzyme-to-substrate 
ratio of 1:100. After overnight incubation at 37°C in a Thermomixer (Eppendorf, France), the 
reaction was quenched with 1 µL of TFA. The digests were subsequently diluted 20-folds in 
either TRIS buffer for trypsin digests, or FA buffer for pepsin digests, to match the dilution 
introduced by the IMER protocol. Digests were stored at 4°C before injection until further 
analysis. 
2.5. LC-MS analysis 
The nano-LC separation of the digests was achieved on a RSLCnano UltiMate 3000 system 
(ThermoFisher Scientific, Le Pecq, France). Peptides were loaded and desalted onto a C18 
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trapping column (Acclaim PepMap100, 300 µm i.d. x 5 mm, 5 µm, ThermoFisher Scientific, Le 
Pecq, France) at a flow rate of 15 µL min-1 in buffer C: 0.05 % TFA in H2O/ACN 98/2 (v/v) for 
5 min, before to be transferred to a C18 column (Acclaim PepMap100 C18, 75 µm i.d. x 
50 cm, 3 µm, 100 Å, ThermoFisher Scientific) at a flow rate of 220 nL min-1 with a gradient 
composed of A (0.1 % FA in H2O/ACN 98/2 (v/v)) and B (0.1 % FA in H2O/ACN 10/90 (v/v)) 
with 2 to 40 % B in 60 min followed by a rapid increase to 90 % B in 1 min. The detection was 
carried out with a nano-ESI QqOrbitrap hybrid mass spectrometer (Q Exactive, ThermoFisher 
Scientific) with the top10 DDA mode: one full MS scan (m/z range 400-2000, resolution 
70,000 at 200 m/z, maximum injection time 100 ms, AGC target 3e6) followed by ten MS/MS 
acquisitions (Top 10, isolation windows 2 m/z, maximum injection time 120 ms, AGC target 
1e5, fixed first mass 90 m/z, resolution 17,500 at 200 m/z, normalized collision energy 25, 
systematic exclusion of z=1 ions and dynamic exclusion of 10 s). 
2.6. Data analysis 
The glycopeptide identification and annotation were performed using PMI-ByonicTM (build 
2.15.7), on a restricted database consisted of 5 annotated sequences from Swiss-Prot 
database associated to hCG sub-units (UniProt accession numbers: P0DN86; P01215; 
P0DN87; A6NKQ9; Q6NT52). The glycan database was the ByonicTM "N-glycan 309 
mammalian no sodium" database. Cleavage residue was set to: i) C-terminal cutter of KR 
aminoacids allowing up to 2 missed cleavages for trypsin digestions; ii) non-specific for 
pepsin digestion. Error tolerance was set to 10 ppm in MS mode and 20 mDa in MS/Ms 
mode. Modifications were set as follows: Carbamidomethylation (Nterm, C, K), Oxidation 
(M), and Deamidation (N, Q) as common1; N-glycan (N) as rare1. Maximum number of 
modifications set to 2 common modifications, 1 rare modification. 
3. Results and discussion 
3.1. Development of IMERs 
3.1.1. Selection of the enzymes 
The aim of this work was to study the potential and the complementarity of protease-based 
IMERs to fasten and improve the reliability of N-glycosylation heterogeneity mapping by 
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testing them with a model glycoprotein, i.e. hCG, a four times N-glycosylated protein. 
Trypsin was chosen because it is the most common protease for bottom-up proteomics. It 
has well-known cleavage sites at the C-terminal side of two amino acids (arginine and lysine) 
that produces peptides with protonable C-terminus amino-acid, and has a high proteolytic 
activity while being very stable under various solvent conditions. A computer simulation of 
expected peptides was carried out with ExPASy server (https://www.expasy.org/) for hCGα 
and all four human gonadotropin hCGβ (Table S.1). It is worth noting that the algorithm of 
the software did not take into consideration R.P trypsin cuts (« Keil rules »). Yet, Rodriguez 
et al. [29] have shown that this cleavage site is not less recurrent than R.C that is considered 
by the server. Therefore, even if not considered by the software, R.P cuts were further 
investigated. 
One tryptic cleavage site was close to αN52. To avoid loss of information caused by steric 
hindrance due to glycosylation, pepsin was also immobilized on a second support because 
pepsin and trypsin do not have the same specificity. Pepsin cleaves proteins at C-terminal 
side of hydrophobic amino acids [21]. 
3.1.2. Preparation of the IMERs 
The selected enzymes were then grafted on Sepharose because this solid support has low 
non-specific interactions with proteins according to a procedure already described by our 
group [15,27]. With evaluation of the amount of enzymes in the supernatant by BCA, the 
grafting yield of trypsin was estimated at 34%, giving a grafting density of trypsin in the 
precolumn up to 1.40 nmol µL-1. Meanwhile, pepsin was grafted on Sepharose beads at 25%. 
Thus, the grafting density of pepsin was estimated at 0.78 nmol µL-1. 
It is worth noting that these grafting yields are consistent with our previous results: trypsin 
and pepsin were immobilized on the same support with a grafting yield of 30% [27] and 24% 
[15], respectively. In all cases, the grafting yield of trypsin was found higher than the one of 
pepsin for the same amount of proteases incubated for immobilization. This difference can 
be explained by the difference of molecular mass between the two (26.6 and 34.6 kDa, 
respectively). Indeed, as trypsin has a lower molecular mass, the kinetic of diffusion is 
further increased and the steric hindrance for its immobilization is lower. 
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3.2. Method developed for the identification of N-glycans by LC-MS in the digest 
To evaluate the potential of these IMERs for the glycosylation mapping of hCG, it was first 
necessary to develop a data processing of the chromatograms and the MS spectra. For this, a 
first digestion was carried out using the T-IMER by transferring a solution of r-hCG (5 µL, 
2.5 µg) on the IMER in the conditions previously described by our group for the digestion of 
Cytochrome C [27]. However, unlike cytochrome C, hCG has five disulfide bonds on hCG 
and 6 on hCG. Therefore, a reduction /alkylation step was carried out to hCG prior to its 
enzymatic digestion to try to prevent from miss-cleavages. The digestion was further 
performed in stop flow mode according to previous studies by our group to increase the 
digestion time and thus the digestion yield. Considering the relative molecular weight of the 
protein to digest a digestion time of 30 min was chosen. 
The digest was analyzed in nanoLC-MS/MS with a routinely used method in proteomics 
involving a C18-based stationary phase and a gradient from 2% of ACN up to about 40% and 
next 90%. The nanoLC format lowers the limits of detection of peptides in ESI-MS by 
reducing the diameter of the separation column. The detection of lower concentrations was 
also favored by a C18 trapping precolumn that allows the injection of high volumes of 
sample (up to 2 µL in this work) on the nanoLC-MS device. The repeatability of the LC-MS 
analysis was studied and the relative standard deviations (RSD) of the retention times of the 
most intense peaks were below 0.5%, thus exhibiting a high repeatability of the analysis. 
Data processing was performed using ByonicTM software. ByonicTM result files display glycan 
composition as unresolved stereoisomers such as "Hex" or "HexNAc". Knowing that N-glycan 
biosynthesis is highly conserved in humans, we completed the structural identity of those 
monosaccharides to be either galactose (Gal), Mannose (Man) or N-acetylglucosamine 
(GlcNAc). Manual validation of the MS/MS spectra (in regard of the quality of the 
fragmented spectrum and the peak annotations) allowed us to propose a scoring threshold 
for each glycosylated peptide. The parameters chosen for the validation of glycopeptide 
identification are summarized in Table 1. As it is known, monosaccharides like fucose can 
rearrange between antennas in CID [30]. While we did not perform fucose-specific linkage 
analysis (such as low collision energy MS/MS), our assumption of core fucosylated glycans 
was often supported by Y-ion Fuc-GlcNAc-peptide such as in the spectrum provided in 
supplementary material (Figure S.1), matching annotated human fucosylated N-glycans. 
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Table 1. ByonicTM score threshold used for the validation of the glycopeptide identification. 
Enzyme Glycosylation site ByonicTM Score 
Pepsin αN52 > 150 
 βN13 > 80 
Trypsin αN52 > 30 
 αN78 > 15 
 βN13 > 10 
 βN30 > 150 
To ensure the identification of glycan moieties, we combined the MS and the 
chromatographic data. As the retention time in reversed-phase LC of a glycopeptide is 
mostly driven by the peptide hydrophobicity, the combination of one given glycosylation site 
and one given peptide was considered. All the glycans that have been identified as bound 
onto these particular peptides by the software formed glycopeptides whose retention times 
were studied by taking into account their respective Extracted Ions Chromatograms (EIC). 
For instance, EICs of glycopeptides from βN13 (CRPIN13LAVEK) are shown on Figure 1. It was 
observed that the addition of a N-acetylneuraminic acid (NeuAc) on the glycan causes an 
increase in the retention time of the glycopeptides (k increases by 20% from the 
monosialylated to the bisialylated glycopeptide). This phenomenon in reversed phase mode 
was already reported in the literature and the explanation proposed was that: (i) the 
hydrophobicity of the glycopeptide containing an additional NeuAc increases due to the 
presence of an acetoamide group [31]; (ii) there are some interactions between the acidic 
moieties of the monosaccharides and active sites on the stationary phase as the same 
phenomenon was observed both in reversed phase and HILIC mode [32,33]. 
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Figure 1. Extracted Ion Chromatograms of glycoforms of CRPIN13ATLAVEK sequence (
βN13) produced 
from r-hCG digestion with T-IMER and analysis by LC-MS/MS exhibiting the influence of sialic acids 
and fucose on the retention time of the glycopeptide (only its glycan moiety was represented). 
Figure 1 also shows the influence of the addition of a fucose (Fuc) that decreases, to a lesser 
extent (k decreases by 1.5% for the biantennary bisialylated glycopeptide), the retention 
time of the glycopeptides. The presence of three hydroxyl groups with fucose should 
contribute to increase the hydrophilicity of the fucosylated glycopeptides [33]. Similarly, the 
influence of the addition of hexose (Hex) and N-acetylglucosamine (GlcNAc) on the retention 
time of the resulting glycopeptides was studied. It was shown that the retention time 
decreases with the addition of one of these neutral monosaccharides because of their 
hydrophilicity.  
Therefore, taking into account the retention time of glycopeptides should help to confirm or 
rule out some identifications made by the software. As an example, a fragmentation 
spectrum that has been attributed to the NV52TSESTCCVAK (
αN52) peptide with the N-glycan 
HexNAc4Hex6Fuc1 (G1) was identified by the software at 17.33 min. Yet, the presence of 
NeuAc was strongly suggested by the identification of a diagnostic fragment ion 
corresponding to the trisaccharide GlcNAc1Gal1NeuAc1 (m/z 657.59 Da). The EIC of G1 has 
shown that its retention time was the same than the same peptide glycosylated with 
GlcNAc4Gal2Man3NeuAc1 (G2) (see Figure 2A). As the addition of a NeuAc strongly increases 
the retention time of the associated glycopeptide, both glycopeptides cannot result from the 
digestion of our sample. As the retention time was close to the one of monosialylated 
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glycopeptides, only the presence of G2 was confirmed. Moreover, the MS/MS spectrum did 
not show any confirmation of the presence of fucose. 
 
Figure 2. (A) Extracted Ions Chromatograms of two glycopeptides identified on αN52 by ByonicTM 
software obtained by the nanoLC-MS/MS analysis of the T-IMER digest of r-hCG. (B) Isotopic MS 
profile combined from 16.08 to 16.6 min. 
This misidentification may come from the software that did not take into account an 
oxidation either on the peptide or on the NeuAc (accounting for the 16 Da mass shift), thus 
misidentified the glycopeptide as the molecular weight of a Fuc and an Hex corresponds to 
the one of a NeuAc and an oxidation with water. Indeed, the isotopic MS profile confirmed 
this oxidation thanks to similar isotopic signature (see Figure 2B). 
On Figure 2A down, no fragmentation spectrum was found for the peak of G3, the observed 
isomer (tr = 16.40 min). By taking into account its retention time (Figure 2A) and its isotopic 
signature, this compound could be identified as an isobar of G2 with the same peptidic and 
glycosidic moiety composition, but having another oxidized function. The difference in 
retention time could also be explained by a difference on the linkage of the neuraminic acid 
(e.g. α2,3 or α2,6 linkage) [34]. As the contribution of the location of NeuAc on the retention 
time is not well understood, the identification has not been confirmed. It is possible to add a 
derivatization step to differentiate them by MS. Linkage-specific derivatization is mostly 
achieved on release glycans rather than proteolytic glycopeptides because it also induces 
peptide modification. This could be very informative when performed between digestion 
and LC-MS/MS. Furthermore, recent publication [35] shows that oxonium ions alone can 
also be informative on sialic acid linkage, thus eliminating the need of linkage-specific 
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derivatization. However, the full characterization of the glycan composition was not judged 
necessary to compare sample handling and digestion protocols on IMERs. 
Therefore, G3 was not taken into consideration, although ByonicTM identified this 
glycopeptide with a score high enough to pass our first validation step. Adding the retention 
time enabled to eliminate false positives from the identified glycopeptides in agreement 
with previous reports [36–38]. 
Similarly, another kind of doubtful identification was proposed by ByonicTM. For instance, a 
glycan composition corresponding to HexNAc4Hex7 on the peptide containing 
αN52 was 
proposed. Yet, the fragmentation spectrum and the analysis of the retention time led to 
think that a sialic acid was also present on the glycan. Knowing that the molecular weight of 
two Hex corresponds to the one of a sialic acid and two oxidations with water, it led to the 
identification of the HexNAc4Gal2Man3NeuAc1 glycan with two oxidations located either on 
the peptide or on the glycan. As the previous misidentification, the glycopeptide was not 
considered for further data processing because of the ambiguity of the location of the 
oxidation either on the peptide or of the NeuAc. 
3.3. Evaluation of the trypsin-based IMER 
3.3.1. Repeatability of the digestion for the glycosylation mapping 
Once having developed this method to control the acceptability of the identification 
provided by ByonicTM, the potential of protease-based IMERs for the mapping of 
glycosylation was studied for the first time. As the digestion efficiency of protease based 
IMERs for the glycosylation mapping was not known, a digestion time of 30 min was chosen 
[15]. In order to compare digestions on IMERs and in solution, the temperature of the 
digestion was set at 37°C on IMERs. 
T-IMER was first studied because it is based on the most used protease. It was used to digest 
r-hCG. The analysis of the digest was performed in triplicate. A chromatogram of the 
resulting digestion is available in Figure S.2A. All the identified glycans in the digest with the 
previously developed method are reported in Table S.2 in the left column. Some different 
results were observed between the three analysis runs (R1, R2, and R3) of the same digest of 
the batch 1 (B1) of r-hCG. Hence, only glycans identified on a specific location in at least two 
out of three runs were further considered as relevant for a given digestion, and most of 
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misidentifications or unresolved compositions (uncertainty between NeuGc and peptidic 
oxidation) were discarded while focusing on the most frequently detected glycopeptides. No 
glycopeptide identified encompasses the αN78 glycosylation site due to potential steric 
hindrance of the carbohydrate moiety. Moreover, the identification of glycopeptides from 
βN30 was not possible because of the lack of sufficient data from the fragmentation spectra 
as the resulting peptide on this site is heavy 
The performance of the digestion with T-IMER was then evaluated by carrying out the 
digestion of a batch of r-hCG drug (batch 1) in triplicate (D1, D2, and D3) and each digest was 
analyzed in triplicate in nanoLC-MS/MS. To study the repeatability of the digestion, the 
identified glycans were considered (see Table S.2, in the mid column). No glycan identified 
on αN52 was fucosylated while glycopeptides from 
βN13 have a higher variability in terms of 
identified glycans (31 different glycans). For the three digestions, the most intense peaks 
were attributed to biantennary and triantennary complex N-glycans. The three independent 
digestions of the r-hCG batch 1 gave 81% of common N-glycans out of 42 identified, 
exhibiting good performances in terms of repeatability of the T-IMER digestions for the 
glycosylation mapping. 
It is noteworthy that all glycans identified on PIN13ATLAVEK (
βN13) were also identified on 
CRPIN13ATLAVEK (
βN13). Yet, further analyses were only performed with the latter even 
though it contains a missed cleavage, because more glycans were identified on this peptide.  
It should also be specified that peptides resulting from the trypsin auto-digestion were 
found in the first digests after the IMER synthesis. The intensity of two of those peptides 
(SSGTSYPDVLK and LGEDNINVVEGNEQFISASK) was then monitored through the different 
digests and it was observed that it decreased by a 1.6 factor between the first digestion and 
the third. This led to think that the post-immobilization washing steps could be further 
optimized to remove non-grafted trypsin from the IMER before its use.  
To further study the repeatability of the digestion on T-IMER, three independent batches of 
hCG were considered (B1, B2, and B3). The analysis of each digest was only achieved in 
duplicate to save time. Therefore, in order to stick at the method previously developed, the 
presence of a glycopeptide was validated if identified in two out of the two runs. The 
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identified glycans can be found in Table S.2 in the right column. Common located N-glycans 
were calculated at 75% out of 40 identified, exhibiting an inter-batch repeatability of the 
digestion with T-IMER for the glycosylation mapping. The lower repeatability for inter-batch 
than a unique batch may be explained by the analysis of the digests only in duplicate. 
Indeed, some glycans may be excluded during the validation process, while a third run might 
have allowed to confirm their presence. Small variations between hCG batches may have 
also contributed to this lower repeatability. 
3.3.2. Comparison of T-IMER with in-solution digestion 
After the evaluation of the repeatability of the digestion on T-IMER in terms of number of 
glycans identified on a specific location, the performance of T-IMER digestion was compared 
to conventional in-solution digestion using the same sample of hCG to confirm the benefit of 
IMERs. As the digestions on IMERs and in solution were carried out with 2.5 µg of hCG, by 
considering an average molecular mass of 35 kDa [24] and taking into account the grafting 
yield, the E/S ratio was evaluated up to 1,430 for T-IMER. This E/S ratio was roughly 150,000 
fold higher than the one of digestion in solution (1:100), thus explaining the short digestion 
time used with IMERs (30 min). 
In order to inject the same quantity of hCG between the two digestion modes, the digest in 
solution was diluted twenty fold to match the concentration resulting from the digestion on 
T-IMER. The results in terms of numbers of glycans identified on a specific location are 
presented in Figure 3. Both digestions shared 93.5% of common N-glycans (42 out of 45) 
with only a 30 min digestion on IMER instead of overnight in solution. Even though, the loss 
of triantennary glycans was noticed on αN52. It is worthwhile to notice that both digestion 
modes involving trypsin led to identified glycans only on αN52 and 
βN13 glycosylation sites and 
no glycan identified on αN78 and 
βN30. Once again, the most intense peaks were attributed to 
glycopeptides containing biantennary and triantennary complex N-glycans for both digestion 
modes. In the end, the digestions on T-IMER led to similar characterization of the 
glycosylation heterogeneity of r-hCG and the same peptides, without missed cleavages (R.P 
cuts were considered insignificant), were identified. Nevertheless, it should also be noted 
that to avoid autoproteolysis, modified proteases can be used. Yet, such enzymes are usually 
more expensive, so the immobilization of trypsin could lead to their reusability, which would 
dramatically decrease the price of a digestion. 
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Figure 3. Comparison of the numbers of N-glycans identified on a specific glycosylation site after the 
digestion of r-hCG with trypsin-based IMER and in solution. 
3.4. Digestions with pepsin-based IMER 
The digestions with T-IMER gave partial information on the N-glycosylation heterogeneity of 
the hCG because of the absence of glycans identified on two N-glycosylation sites (αN78
 and 
βN30). To complete this characterization, a digestion with P-IMER was considered. The 
repeatability of the pepsic digestion was already studied by our group [15]. Therefore, P-
IMER was used to carry out the digestion of an hCG batch (batch 1). A chromatogram of the 
resulting digestion is available in Figure S.2B. The comparison of the peptides with a 
glycosylation site successfully identified after digestion with T-IMER and P-IMER is presented 
in Table S.3. The digestion with P-IMER led to more heterogeneous glycopeptides for one 
glycosylation site than with T-IMER, as the proteolysis site-specificity of pepsin is lower than 
that of trypsin. Besides, the comparison of the glycosylation mapping obtained using T-IMER 
and P-IMER is depicted in Figure 5. It should be mentioned that the structure propositions 
are primarily based on the sugar composition inferred from common annotated structures 
and fragmentation spectra. One should notice that for αN52 and 
βN13, there are more glycans 
identified with trypsin than pepsin due to the overall variability in terms of peptide that 
tends to decrease the signal intensity of each glycopeptide since one given glycan can be 
present on several peptides varying in length. Therefore, due to the lower signal-to-noise 
ratio, the probability to have an informative fragmentation spectrum decreases. 
Nevertheless, the digestion with P-IMER allowed the identification of glycans on αN78 and 
βN30, thus highlighting the complementary of trypsin and pepsin. Moreover, common glycans 
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localized on a specific N-glycosylation site were evaluated down to 39% between both 
enzymes, highlighting the complementarity of the two enzymes to identify a maximum 
number of N-glycans. Although this was only a qualitative study, the results were also 
compared to what can be found in literature [39,40]. It was reported that hCG contains 
mostly complex glycans, especially hCGβ. In this study, the combination of pepsin and 
trypsin allowed the identification of 48% of complex glycans on hCGβ. 
 
Figure 4. Comparison of the numbers of N-glycans identified on a specific glycosylation site after the 
digestion of r-hCG with pepsin-based IMER and in solution. 
The performance of the digestion with P-IMER was also compared with a pepsin digestion in 
solution. As for T-IMER, the E/S ratio was evaluated and a value up to 800 was calculated for 
P-IMER. Even if the E/S ratio is lower than for T-IMER, it is still 80,000 fold higher than the 
ratio used for digestion in solution (1:100). The results in terms of glycans identified on a 
specific location are presented in Figure 4. Noticeably, according to the glycosylation site, 
either IMER or in-solution digestion was more efficient. As an example, IMER led to the 
identification of three additional glycans on αN52, whereas the digestion in solution led to 
seven additional glycans on αN78. Unlike tryptic digestions, both digestions shared only 59.5% 
of common glycans localized on a specific N-glycosylation site. Among the common 
identified glycans located on a given site, biantennaries and triantennaries were the most 
intense. Yet, less intense glycans (e.g. hybrids and high mannose) were specifically identified 
with the pepsin digestion either in-solution or with P-IMER (see Figure 4). This was surprising 
because pepsin digestion provides more variable peptides that get the glycans, so there is a 
possibility of decrease of signal for one site of glycosylation. One explanation could be the 
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specificity of each enzyme to cleave the protein with potential steric hindrance of the sugar 
moieties. 
As pepsin and trypsin are complementary, it would have been interesting to immobilize both 
enzymes on the same support. Yet, the optimum pH for digestion with trypsin is 8.0 while it 
is 2.0 for pepsin. Therefore, if co-immobilization is considered one of the enzymes would be 
inactive. Moreover, the activity of pepsin is decreasing rapidly and is practically zero above a 
pH of 5.5. Yet, if in a pH range from 5.5 to 7.0-7.5 the pepsin is stable and a simple return to 
a lower pH of 2.0 allows to recover a full activity of the enzyme, a pH greater than 7.5 
irreversibly inactivates the pepsin [41] which will not allow its use once grafted. 
  
 
Figure 5. Glycans identified on glycopeptides after digestions on trypsin- and pepsin-based IMERs of r-hCG and analysis by LC-MS/MS. (Common identified N-
glycans between both enzymes: 39%). 
  
 
Figure 6. Glycans identified on glycopeptides after digestions on trypsin- and pepsin-based IMERs of u-hCG and analysis by LC-MS/MS. (Common identified N-
glycans between both enzymes: 41%).
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3.5. Potential of the IMERs for the glycosylation mapping 
Having established the repeatability of the IMER digestion and the complementarity of our 
two IMERs for N-glycan mapping, the potential of the supports was further evaluated for the 
discrimination of hCG varying in production way. This is why a second hCG-based drug was 
considered. The source of production between the two drugs is different as r-hCG is a 
recombinant one expressed in Chinese Hamster Ovary cells while u-hCG is extracted from 
urine of pregnant women. Therefore, one can expect that they have two different 
glycosylation profiles. It is of interest to characterize the glycosylation profile because it is 
related to the biological activity of the protein [42]. The potential of the two IMERs for their 
digestion combined with LC-MS/MS analysis was evaluated in order to see if the fast N-
glycosylation mapping led to significantly different results. 
The analysis of the digests was carried out in duplicates and only glycans identified in both 
runs were further considered. The glycosylation mapping of u-hCG is reported in Figure 6. 
Once again, one should note the complementarity of trypsin and pepsin for the glycosylation 
mapping of u-hCG as only pepsin allowed the identification of glycans on αN78 and 
βN30. 
Surprisingly, it seemed at first that the total number of glycans identified on the 
glycosylation sites was roughly the same between the two drugs. It is also noteworthy that 
the most intense peaks obtained with both digestions were attributed to complex N-glycans, 
thus being in good agreement with previous studies [39,40].  
To compare the two drugs in detail, the characteristics of the N-glycans identified thanks to 
the digestions with both IMERs were compared for each drug and each glycosylation site 
(Table 2). It appears that both drugs have some similar characteristics. As an example, 
fucosylated glycans are not found on hCGα while most glycans identified on βN30 are 
fucosylated. The amount of glycans lacking sialic acids is also quite similar for r-hCG and u-
hCG on each glycosylation site. With the exception on βN13, the number of biantennary 
glycans is about the same for both drugs. But, Table 2 also demonstrates that both drugs 
have significantly different N-glycosylation mappings. For instance, glycans containing 
GalNAc were only identified in u-hCG. Moreover, the number of biantennary glycans was 
higher for u-hCG than for r-hCG. 
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Table 2. Comparison of the N-glycosylation mapping of r-hCG (batch 1) and u-hCG based on a relative 
qualitative characterization of the N-glycans identified on each N-glycosylation site after digestions 
on T-IMER and P-IMER and analysis by LC-MS/MS. 
αN52 r-hCG u-hCG  βN13 r-hCG u-hCG 
High mannose 9% (1) 8% (1)  High mannose 19% (6) 10% (3) 
Monoantennary 64% (7) 62% (8)  Monoantennary 41% (13) 26% (8) 
Biantennary 27% (3) 31% (4)  Biantennary 19% (6) 52% (16) 
Triantennary - -  Triantennary 22% (7) 13% (4) 
Not sialylated 46% (5) 54% (7)  Not sialylated 50% (16) 42% (13) 
Fucosylated - -  Fucosylated 25% (8) 39% (12) 
GalNAc containing - 8% (1)  GalNAc containing - 16% (5) 
Total number 11 13  Total number 32 31 
   
 
   
αN78 r-hCG u-hCG  βN30 r-hCG u-hCG 
High mannose 14% (1) -  High mannose - - 
Monoantennary  - 40% (2)  Monoantennary - 20% (1) 
Biantennary 43% (3) 40% (2)  Biantennary 75% (3) 80% (4) 
Triantennary 43% (3) 20% (1)  Triantennary 25% (1) - 
Not sialylated 14% (1) -  Not sialylated 25% (1) - 
Fucosylated - -  Fucosylated 100% (4) 80% (4) 
GalNAc containing - -  GalNAc containing - - 
Total number 7 5  Total number 4 5 
* Number of corresponding identified N-glycans 
4. Conclusions 
Two IMERs prepared by immobilizing either trypsin or pepsin were applied to the N-
glycosylation mapping of a model highly glycosylated protein, i.e. hCG. After the evaluation 
of the repeatability of the analysis of a digest using T-IMER by nanoLC-MS/MS, each 
identified glycopeptide was validated by considering its retention time. This allowed to 
invalidate in-source fragmentation of two identifications that differ from a single 
monosaccharide thanks to differences in retention time of the glycopeptides. The 
identification of 81% of common N-glycans of a given batch of hCG highlighted the 
repeatability of the IMER digestion. Finding also 93.5% of common N-glycans after an 
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overnight digestion in solution and only 30 min using the IMER highlighted also the great 
potential of IMERs for glycosylation mapping. 
The use of a pepsin-based IMER on the same hCG batch next demonstrated the 
complementarity of both IMERs. Indeed, despite trypsin allowed the identification of more 
glycans than pepsin on a specific glycosylation location, two of the four N-glycosylation sites 
were only characterized with a digestion with pepsin. The potential of these IMERs for 
glycosylation mapping was also demonstrated with the digestion of two hCG-based drugs 
leading to significantly different results. At last, IMERs could notably increase the 
performances of the whole analytical procedure due to their possible re-use, the low 
digestion time, and their possible integration in an on-line fully automated LC-MS set-up that 
decrease the analysis cost and improve accuracy. 
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Table S.1. In silico simulation of the expected glycopeptides from human hCG for a digestion with 
trypsin. (N-glycosylation sites are tagged in bold). Data obtained from https://www.expasy.org/. 
α subunit Resulting peptide sequence Peptide mass [Da] 
αN52 N52VTSESTCCVAK 1241.397 
αN78 VEN78HTACHCSTCYYHK 1896.100 
   
β subunit Resulting peptide sequence Peptide mass [Da] 
βN13 CRPIN13ATLAVEK 1314.566 
βN30 EGCPVCITVN30TTICAGYCPTMTR 2433.871 
 
 
  
Table S.2.  Identified glycans and proposed structures for each N-glycosylation site after digestion with T-IMER of r-hCG, LC-MS analysis, and data treatment. 
Repeatability of three analysis (R1, R2, and R3)) of one digest of hCG (batch 1, B1), of three digestions (D1, D2, and D3) of hCG (B1), and of three hCG batches 
(B1, B2, and B3). 
Glycosylation site 
α
N52 Proposed structure 
 Repeatability of the analysis  Repeatability of the digestion  Repeatability batch-to-batch 
 R1 R2 R3  D1 D2 D3  B1 B2 B3 
HexNAc(2)Hex(5) 
 
 X X X  X X X  X X X 
HexNAc(2)Hex(6) 
 
 
          X 
HexNAc(3)Hex(4) 
 
 X X X  X X X  X  X 
HexNAc(3)Hex(4)NeuAc(1) 
 
 
X X X  X X X  X X X 
HexNAc(3)Hex(5) 
 
 
X X X  X X X  X X X 
HexNAc(3)Hex(5)NeuAc(1) 
 
 
X X   X X X  X X X 
HexNAc(3)Hex(6) 
 
 
          X 
HexNAc(3)Hex(6)NeuAc(1) 
 
 
X X X  X X X  X  X 
HexNAc(4)Hex(4) 
 
 
 X X  X X X  X X X 
HexNAc(4)Hex(4)NeuAc(1) 
 
 
 X X  X X X  X  X 
HexNAc(4)Hex(5) 
 
 X X X  X X X  X X X 
HexNAc(4)Hex(5)NeuAc(1) 
 
 
X X X  X X X  X X X 
HexNAc(4)Hex(5)NeuAc(2) 
 
 
X X   X X X  X X X 
Glycosylation site 
β
N13 Proposed structure 
 Repeatability of the analysis  Repeatability of the digestion  Repeatability batch-to-batch 
 R1 R2 R3  D1 D2 D3  B1 B2 B3 
HexNAc(2)Hex(10) 
 
 
X X X  X X X  X X X 
  
Glycosylation site 
β
N13  
(continued) 
Proposed structure 
 Repeatability of the analysis  Repeatability of the digestion  Repeatability batch-to-batch 
 R1 R2 R3  D1 D2 D3  R1 R2 R3 
HexNAc(2)Hex(5) 
 
 X X X  X X X  X X X 
HexNAc(2)Hex(6) 
 
 
     X      
HexNAc(2)Hex(7) 
 
 
X X X  X X X  X X X 
HexNAc(2)Hex(8) 
 
 
 X X  X X X  X X X 
HexNAc(3)Hex(3) 
 
 
     X X     
HexNAc(3)Hex(4) 
 
 X X X  X X X  X X  
HexNAc(3)Hex(4)NeuAc(1) 
 
 
X X X  X X X  X X X 
HexNAc(3)Hex(5) 
 
 
X X X  X X X  X X X 
HexNAc(3)Hex(5)NeuAc(1) 
 
 
X X X  X X X  X X X 
HexNAc(3)Hex(6) 
 
 
X X X  X X X  X X  
HexNAc(3)Hex(6)NeuAc(1) 
 
 
X X X  X X X  X X X 
HexNAc(4)Hex(4) 
 
 
X X X  X X X  X X X 
HexNAc(4)Hex(4)Fuc(1) 
 
 
     X X  X X X 
HexNAc(4)Hex(4)Fuc(1)NeuAc(1) 
 
 
      X  X  X 
HexNAc(4)Hex(4)NeuAc(1) 
 
 
X X X  X X X  X X X 
              
  
Glycosylation site 
β
N13  
(continued) 
Proposed structure 
 Repeatability of the analysis  Repeatability of the digestion  Repeatability batch-to-batch 
 R1 R2 R3  D1 D2 D3  R1 R2 R3 
HexNAc(4)Hex(5) 
 
 
X X X  X X X  X X X 
HexNAc(4)Hex(5)Fuc(1) 
 
 
X X X  X X X  X X X 
HexNAc(4)Hex(5)Fuc(1)NeuAc(1) 
 
 
X X X  X X X  X X X 
HexNAc(4)Hex(5)Fuc(1)NeuAc(2) 
 
 
X X X  X X X  X X X 
HexNAc(4)Hex(5)NeuAc(1) 
 
 
X X X  X X X  X X X 
HexNAc(4)Hex(5)NeuAc(2) 
 
 
X X X  X X X  X X X 
HexNAc(4)Hex(6) 
 
 
      X     
HexNAc(4)Hex(6)NeuAc(1) 
 
 
X  X  X  X     
HexNAc(5)Hex(6) 
 
 
     X X  X  X 
HexNAc(5)Hex(6)Fuc(1)NeuAc(1) 
 
 
     X X  X  X 
HexNAc(5)Hex(6)Fuc(1)NeuAc(2) 
 
 
X X X  X X X  X X X 
HexNAc(5)Hex(6)Fuc(1)NeuAc(3) 
 
 
X X X  X X X  X X X 
HexNAc(5)Hex(6)NeuAc(1) 
 
 
X X X   X X  X X X 
              
              
  
Glycosylation site 
β
N13  
(continued) 
Proposed structure 
 Repeatability of the analysis  Repeatability of the digestion  Repeatability batch-to-batch 
 R1 R2 R3  D1 D2 D3  R1 R2 R3 
HexNAc(5)Hex(6)NeuAc(2) 
 
 
X X X  X X X  X X X 
HexNAc(5)Hex(6)NeuAc(3) 
 
 
X X X  X X X  X X X 
  
Table S.3. Peptides (> 5 amino acids) with glycosylation site identified by ByonicTM after a digestion on T-IMER and on P-IMER of r-hCG (batch 1) and analysis by 
LC-MS/MS. 
αN52 Peptide sequence after digestion on T-IMER Peptide sequence after digestion on P-IMER 
 N52VTSESTCCVAK SRAYPTPLRSKKTMLVQKN52VTSE 
    RAYPTPLRSKKTMLVQKN52VTSES 
           PTPLRSKKTMLVQKN52VTSESTCC 
                                     VQKN52VTSESTCCVAKSYNRVTVMGGF 
                                     VQKN52VTSESTCCVAKSYNRVTVMGG 
                                     VQKN52VTSESTCCVAKSYNRVTVM 
                                     VQKN52VTSESTCCVAKSYNRV 
                                     VQKN52VTSESTCCVAKSYNRVTV 
                                     VQKN52VTSESTCCVAKSYNRVTVMG 
                                     VQKN52VTSESTCCVAKSYN 
                                     VQKN52VTSESTCCVAKS 
                                     VQKN52VTSESTCC 
                                       QKN52VTSESTCCV 
                                          KN52VTSESTCCVAKSYNRVTVM 
αN78 Peptide sequence after digestion on T-IMER Peptide sequence after digestion on P-IMER 
 - NRVTVMGGFKVEN78HTACHCSTCY 
              MGGFKVEN78HTACHCSTC 
  
                  GGFKVEN78HTACHCSTCY 
                  GGFKVEN78HTACHCSTCYYHKS 
αN78 
(continued) 
Peptide sequence after digestion on T-IMER Peptide sequence after digestion on P-IMER 
                  GGFKVEN78HTACHCSTC 
                     GFKVEN78HTACHCSTCY 
 -                    GFKVEN78HTACHCSTC 
                          KVEN78HTACHCSTCY 
                          KVEN78HTACHCSTC 
βN13 Peptide sequence after digestion on T-IMER Peptide sequence after digestion on P-IMER 
 CRPIN13ATLAVEK TWASKEPLRPRCRPIN13ATL 
      PIN13ATLAVEK       ASKEPLRPRCRPIN13ATL 
           SKEPLRPRCRPIN13ATL 
           SKEPLRPRCRPIN13ATLA 
                EPLRPRCRPIN13ATL 
                  PLRPRCRPIN13AT 
                  PLRPRCRPIN13ATLA 
                         PRCRPIN13ATLAVEKEG 
                                      N13ATLAV 
βN30 Peptide sequence after digestion on T-IMER Peptide sequence after digestion on P-IMER 
βN30 - ITVN30TTIC 
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Figure S.1. MS/MS spectrum of a glycopeptide identified on βN13 after a tryptic digestion 
 
 
Figure S.2. Base Peak Chromatogram obtained after a digestion of 2.5 µg of r-hCG on (A) T-IMER and 
(B) P-IMER followed by a nanoLC-MS/MS analysis 
